GlassScriptPhysician profile
Bryan Kirk Eastes
NPI 1336157866
$4,066.10
in general payments reported to CMS, 2019-2025
30 companies · $976 in 2025
The $976 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $181 · 2021: $118 · 2022: $144 · 2023: $1,012 · 2024: $919 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $539.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $494.09 | 2022-2025 | Linzess, Viberzi, Creon |
| Glaxosmithkline, LLC. | $475.56 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $425.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $412.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $261.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $239.98 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $181.78 | 2023-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $127.93 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $122.95 | 2024-2025 | Rexulti |
| Allergan, INC. | $89.31 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $82.50 | 2019-2020 | |
| Amgen INC. | $71.65 | 2023-2025 | Repatha, Krystexxa, Repatha |
| Sunovion Pharmaceuticals INC. | $60.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $51.55 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $50.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.41 | 2022-2025 | Zoryve, Seglentis, Livalo |
| Sumitomo Pharma America, INC. | $38.44 | 2023-2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $37.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.78 | 2024 | Jardiance |
| Abbott Laboratories | $31.67 | 2022 | |
| Medtronic, INC. | $31.36 | 2023 | Interstim |
| Phathom Pharmaceuticals, INC. | $28.16 | 2023 | Voquezna |
| Smith+Nephew, INC. | $26.94 | 2019 | |
| Merck Sharp & Dohme LLC | $23.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.28 | 2024 | |
| Astellas Pharma US INC | $19.68 | 2019 | |
| Horizon Therapeutics Plc | $18.44 | 2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Eastes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.